摘要
目的:分析杀伤细胞免疫球蛋白样受体(KIR)及其特异性配体HLAⅠ类分子在江苏地区汉族人群的分布特点。方法:分别利用real-time PCR法和PCR-SSP方法对173例无血缘关系的江苏汉族健康人群进行KIR和HLA-Cw,HLA-Bw4分型,并分析KIR/HLA配对组合的类型和数量。结果:江苏汉族人群中,>92%的个体同时表达四种抑制性KIR(iKIR)(2DL1,2DL2/3,3DL1,3DL2)。2DL2/HLA-C1,2DL3/HLA-C1,2DL1/HLA-C2,3DL1/Bw4的频率分别依次分别为0.243,0.971,0.457,0.590;2DS1/HLA-C2,2DS2/HLA-C1的频率为0.162,0.231。54.3%的个体只表达2DL1而不表达相应的配体HLA-C2,32.9%的个体只表达3DL1而缺乏配体HLA-Bw4,另有5.8%的个体只表达HLA-Bw4而不表达3DL1。27.7%的个体同时表达3种iKIR/HLA,26%的个体同时表达两种iKIR/HLA,25.4%的个体只遗传一个iKIR/HLA配对,未发现3种iKIR/HLA同时缺失的个体。结论:在江苏汉族人群中,存在KIR与HLA表型分离现象,抑制性KIR/HLA配对表达高于刺激性KIR/HLA配对,约1/4个体只表达单个iKIR/HLA配对。
AIM: To investigate the distribution of killer cell immunoglobulin-like receptor(KIR) and its specific ligand human leukocyte antigen(HLA) in Jiangsu Han population.METHODS: 173 samples from unrelated healthy individuals of Jiangsu Han population were genotyped and observed for KIR,HLA-Cw and HLA-Bw4 using a SYBR Green I real-time PCR and PCR-SSP method,respectively.The number and type of KIR/HLA pairs inherited in each individual were analyzed.RESULTS: In Jiangsu Han population,all four inhibitory KIR(2DL1,2DL2/3,3DL1 and 3DL2) that recognize the classical HLA class I molecules HLA-A,-B and-C were present in 92% of the study group.Frequencies of 2DL2/HLA-C1,2DL3/HLA-C1,2DL1/HLA-C2 and 3DL1/Bw4 were 0.243,0.971,0.457 and 0.590,respectively;frequencies of 2DS1/HLA-C2 and 2DS2/HLA-C1 were 0.162 and 0.231,respectively.54.3% of the cases expressed KIR2DL1 without HLA-C1,32.9% inherited 3DL1 without HLA-Bw4 and 5.8% expressed HLA-Bw4 without 3DL1.27.7% of the individuals had three iKIR/HLA pairs,26% carried two iKIR/HLA pairs,and 25.4% inherited a single iKIR/HLA pair and no one was deficient in all three iKIR/HLA pairs.CONCLUSION: There was disparity between KIR receptor and HLA ligand in Jiangsu Han population.Inhibitory KIR/HLA pair frequency was higher than stimulatory one.About 1/4 of the study group expressed a single iKIR/HLA pair alone.
出处
《细胞与分子免疫学杂志》
CAS
CSCD
北大核心
2012年第8期863-865,868,共4页
Chinese Journal of Cellular and Molecular Immunology
基金
武进科技计划项目(WS2010012)